The Mixed Dyslipidemia drugs in development market research report provides comprehensive information on the therapeutics under development for Mixed Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mixed Dyslipidemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Mixed Dyslipidemia by nine companies/universities/institutes. The top development phase for Mixed Dyslipidemia is phase ii with four drugs in that stage. The Mixed Dyslipidemia pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Mixed Dyslipidemia pipeline products market are: Arrowhead Pharmaceuticals, Eli Lilly and Co and Shanghai Junshi Biosciences.
The key targets in the Mixed Dyslipidemia pipeline products market include Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3), Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.), and Apolipoprotein C III (APOC3).
The key mechanisms of action in the Mixed Dyslipidemia pipeline product include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) Inhibitor with three drugs in Pre-Registration. The Mixed Dyslipidemia pipeline products include four routes of administration with the top ROA being Subcutaneous and four key molecule types in the Mixed Dyslipidemia pipeline products market including Antisense RNAi Oligonucleotide, and Monoclonal Antibody.
Mixed Dyslipidemia overview
Dyslipidemia is a condition where the lipid levels in blood are either low or high. While in mixed dyslipidemia the levels of LDL (low density lipoprotein) and TG (triglycerides) are elevated, and HDL (high density lipoprotein) is low. This occurs when there is an overproduction of very low-density lipoprotein (VLDL) leading to an increase in LDL and TG. People with mixed dyslipidemia are at risk of developing coronary heart disease (CHD) and atherosclerosis. It is prevalent in 0.5 to 8.8 % of the general population. Underlying diseases, genetic inheritance, age, obesity, and alcohol abuse are common factors associated with this condition. Diagnosed by lipid profile test (LPD) where the levels are assessed. Statins are the first line of therapy and then bile acid sequestrants, fibrates, and a healthy diet are recommended.
For a complete picture of Mixed Dyslipidemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
